In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. The company is positioned at the intersection of precision oncology and diagnostic innovation, with recent strategic partnerships like the multi-year collaboration with Merck announced in January 2026. Clinical validation, regulatory wins, and operational efficiencies are improving reimbursement prospects and accelerating the company's path to profitability.
Cyborg Score Rationale
With a market capitalization of $13.6B and trailing twelve month revenue of $903M, Guardant Health demonstrates strong market position and rapid growth. In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year, indicating solid momentum in a high-growth oncology diagnostics market.
Top Insights
Multi-year strategic collaboration agreement announced with Merck (January 2026) to develop companion diagnostics using Guardant Infinity Smart Platform
FDA approval for Shield liquid biopsy for colorectal cancer screening (2024)
According to 21 analysts, the average rating for GH stock is Strong Buy
Over 500,000 blood tests performed by 12,000 doctors to date
Named Competitors
Exact Sciences — Precision oncology and cancer screening tests
Natera — Genetic testing and liquid biopsy solutions
Foundation Medicine — Molecular oncology testing services
Illumina — DNA sequencing and genomic analysis
Recent Developments
(January 2026) Multi-year strategic collaboration with Merck for companion diagnostics development
(January 2026) FDA approval for Guardant360 CDx as companion diagnostic for BRAFTOVI combination therapy
(December 2025) Collaboration with Trial Library to increase access to cancer clinical trials
(December 2025) In-house liquid biopsy testing service launch in Italy with Policlinico Gemelli
Open the full interactive Guardant Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.